Zhejiang Tailin BioEngineeringLtd Past Earnings Performance
Past criteria checks 1/6
Zhejiang Tailin BioEngineeringLtd has been growing earnings at an average annual rate of 3.9%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 10.5% per year. Zhejiang Tailin BioEngineeringLtd's return on equity is 1%, and it has net margins of 2.9%.
Key information
3.9%
Earnings growth rate
-0.8%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 10.5% |
Return on equity | 1.0% |
Net Margin | 2.9% |
Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Recent updates
Zhejiang Tailin BioEngineering Co.,Ltd's (SZSE:300813) 42% Share Price Surge Not Quite Adding Up
May 09Zhejiang Tailin BioEngineeringLtd's (SZSE:300813) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 01Zhejiang Tailin BioEngineering Co.,Ltd's (SZSE:300813) Shares Climb 32% But Its Business Is Yet to Catch Up
Mar 08Revenue & Expenses Breakdown
How Zhejiang Tailin BioEngineeringLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 271 | 8 | 78 | 59 |
31 Dec 23 | 270 | 20 | 77 | 58 |
30 Sep 23 | 343 | 54 | 81 | 68 |
30 Jun 23 | 371 | 72 | 77 | 66 |
31 Mar 23 | 381 | 83 | 73 | 65 |
01 Jan 23 | 374 | 80 | 72 | 64 |
30 Sep 22 | 335 | 68 | 71 | 64 |
30 Jun 22 | 318 | 67 | 66 | 62 |
31 Mar 22 | 307 | 68 | 64 | 59 |
01 Jan 22 | 283 | 64 | 63 | 55 |
30 Sep 21 | 249 | 58 | 51 | 48 |
30 Jun 21 | 225 | 58 | 51 | 41 |
31 Mar 21 | 208 | 51 | 51 | 38 |
31 Dec 20 | 200 | 48 | 52 | 38 |
30 Sep 20 | 192 | 42 | 50 | 38 |
30 Jun 20 | 185 | 36 | 46 | 37 |
31 Mar 20 | 182 | 37 | 42 | 33 |
31 Dec 19 | 181 | 34 | 42 | 29 |
30 Sep 19 | 172 | 45 | 40 | 23 |
31 Dec 18 | 159 | 48 | 30 | 21 |
31 Dec 17 | 142 | 45 | 43 | 0 |
30 Jun 17 | 120 | 33 | 40 | 0 |
31 Mar 17 | 116 | 31 | 39 | 0 |
31 Dec 16 | 112 | 29 | 37 | 0 |
30 Sep 16 | 109 | 27 | 39 | 0 |
30 Jun 16 | 107 | 24 | 41 | 0 |
31 Mar 16 | 95 | 20 | 39 | 0 |
31 Dec 15 | 82 | 15 | 36 | 0 |
30 Sep 15 | 73 | 14 | 33 | 0 |
30 Jun 15 | 64 | 12 | 30 | 0 |
31 Dec 14 | 59 | 10 | 28 | 0 |
31 Dec 13 | 94 | 21 | 32 | 0 |
Quality Earnings: 300813 has a high level of non-cash earnings.
Growing Profit Margin: 300813's current net profit margins (2.9%) are lower than last year (21.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300813's earnings have grown by 3.9% per year over the past 5 years.
Accelerating Growth: 300813's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300813 had negative earnings growth (-90.4%) over the past year, making it difficult to compare to the Life Sciences industry average (0.7%).
Return on Equity
High ROE: 300813's Return on Equity (1%) is considered low.